Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Young Blood Institute’s AmβARI study on Amyloid Removal
Retrieved on:
星期二, 十二月 12, 2023
Amyloid plaques are a hallmark of several neurodegenerative diseases, including Alzheimer’s Disease (AD).
Key Points:
- Amyloid plaques are a hallmark of several neurodegenerative diseases, including Alzheimer’s Disease (AD).
- The collaboration is focused on using [F-18]NAV-4694 as an imaging biomarker in the YBI AmβARI (Amyloid βeta Assessment & Removal Intervention) study.
- The Young Blood Institute will utilize Meilleur’s [F-18]NAV-4694 tracer to aid YBI’s study of early detection and clearance of Amyloid βeta to prevent Alzheimer’s disease using Therapeutic Plasma Exchange.
- Our goal is to expand the availability of this novel investigational imaging agent to the broader scientific community.”